GlassScriptPhysician profile
Mark H Lazar
NPI 1578578308
$1,233.44
in general payments reported to CMS, 2019-2025
17 companies · $135 in 2025
The $135 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $322 · 2020: $114 · 2021: $162 · 2022: $276 · 2023: $108 · 2024: $116 · 2025: $135.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $359.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $359.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $278.65 | 2019-2025 | |
| Novo Nordisk INC | $218.36 | 2019-2025 | Wegovy, Rybelsus |
| Glaxosmithkline, LLC. | $163.39 | 2019-2024 | Trelegy Ellipta, Shingrix |
| Janssen Pharmaceuticals, INC | $161.09 | 2019-2023 | Xarelto |
| Amgen INC. | $69.64 | 2023-2024 | Repatha, Otezla, Prolia |
| Abbvie INC. | $56.57 | 2021-2022 | |
| Boston Scientific Corporation | $55.25 | 2025 | General - Pain Management |
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.82 | 2021-2022 | |
| Exact Sciences Corporation | $28.92 | 2025 | The Cologuard Plus Collection Kit |
| Vanda Pharmaceuticals INC. | $25.60 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $24.52 | 2021 | |
| Amarin Pharma, INC. | $22.61 | 2022 | |
| Allergan, INC. | $18.24 | 2019 | |
| Novartis Pharmaceuticals Corporation | $18.04 | 2022 | |
| Almatica Pharma LLC | $14.31 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kci USA, INC. | $12.43 | 2019 | |
| Lilly USA, LLC | $12.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Lazar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.